Latest news from
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy and Cookie Notice
CNX Therapeutics appoints Ben Moore as Vice President, Corporate Development
CNX Therapeutics is proud to announce that Ben Moore has joined CNX Therapeutics as our Vice President, Corporate Development.
Ben has worked in the pharmaceutical industry for over 15 years and joins from Mundipharma International where he was Senior Director, Corporate and Business Development.
CNX Therapeutics appoints Lee Debenham as Director of Scientific Affairs
CNX Therapeutics is delighted to welcome Lee Debenham as our new Director of Scientific Affairs.
Lee has worked in the pharmaceutical industry for 24 years and joins CNX from Bristol-Myers Squibb where he was Associate Director RCEE, and previously held roles at Celgene and Allergan.
CNX Therapeutics acquires Synchrony Pharma, a company specialising in hospital-speciality pharmaceutical products
CNX Therapeutics has embarked on its buy-and build strategy, successfully completing the acquisition of Synchrony Pharma, a company specialising in the development and commercialisation of niche injectable pharmaceuticals.
CNX Therapeutics appoints Jeremy Devaney as Vice President, Commercial Operations
CNX Therapeutics is delighted to announce that Jeremy Devaney has joined CNX Therapeutics as Vice President, Commercial Operations.
CNX Therapeutics moves into new London office space
Our new office is within LABS House, a modern and well-equipped serviced office building offering a number of amenities and communal spaces. We believe that this flexible and collaborative way of working will be the ideal environment for us to achieve our goal of building a successful European business.